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EDITORIAL
The Enigma of Vitamin D Role in Inflammation
Vitamin D is a widely studied molecule, but several aspects of its biologic behaviour remain unclear. Despite having
been considered for decades solely as a co-actor of the bone metabolism regulation, multiple experimental observations
have suggested a role in different fields of human physiology [1]. Notably, numerous authors attributed to vitamin D
key  functions  in  the  regulation  of  the  immune  system  [2  -  12],  hence  revealing  its  potential  contribution  in  the
management of inflammatory diseases [13 - 22].
However, as well as for other promising molecules under investigation, a significant gap between the strength of the
in vitro data and the weakness of the in vivo observations still exists. There are several reasons beyond this discrepancy:
for  instance,  experimental  conditions  in  vitro  cannot  replicate  the  complex  regulation  of  the  vitamin  D-dependent
pathways  in  vivo;  moreover,  vitamin  D  concentrations  used  in  vitro  are  generally  significantly  higher  than  those
physiologically  measured  in  human  subjects.  To  date,  the  real  and  actual  impact  of  the  vitamin  D  status  on
inflammation  in  vivo  is  still  an  enigma.  Consequently,  whether  or  not  vitamin  D  plays  a  relevant  role  in  the
development and management of inflammatory diseases is still a matter of debate. If, on the one side, we should not
neglect vitamin D potentialities, on the other side, we must avoid considering it a “panacea”, as this misinterpretation
might lead to overtreatment with direct and indirect relevant costs [23, 24].
A large-scale screening and supplementation strategies for therapeutic indications other than the maintenance of
bone  homeostasis  are  currently  not  supported  by  the  available  evidence,  and  their  clinical  advantage  and  cost-
effectiveness  are  doubtful.
In this special issue, contributions from eminent figures in this field have been gathered to try to elucidate what we
already know and what is new about vitamin D and inflammation.
At first, Trombetta and colleagues [25] extensively and comprehensively revised the current knowledge about the in
vivo  and  in  vitro  vitamin  D  activity  on  the  immune  system regulation  and  its  implications  for  the  development  of
autoimmune diseases.  To deepen the insights on specific pathological  conditions,  Nerviani et  al.  [26] reviewed the
relevant literature about the impact of the vitamin D status on the clinical course of Systemic Lupus Erythematosus
(SLE). In this manuscript, the authors presented the available data assessing the effects of vitamin D on several markers
of disease activity, further discussing the evidence supporting a role for vitamin D supplementation in the management
of SLE. The specific relationship with the antiphospholipid antibody syndrome has been revised in depth by Gualtierotti
and colleagues [27], who also included original data showing the in vitro effects of vitamin D supplementation on the
endothelial perturbation in this condition.
In the context of inflammatory arthritis, Crotti and colleagues [28] discussed the current evidence about the role of
vitamin D in the development of spondyloarthritis; here the authors not only underpinned the discrepancies existing in
this field, but also stressed the relevance that vitamin D status seems to have in the occurrence of some critical co-
morbidities in the course of systemic inflammatory diseases.
Resulting from the impairment of several biological pathways involved in the bone metabolism, osteoporosis and
increased risk of fracture are common in inflammatory arthritis. Bone health and immune system are strictly related,
and  their  complex  and  intriguing  connections  are  the  matter  of  study  of  a  recently  developed  field  known  as
“osteoimmunology”. In this regards, Sainaghi and Gibbin [29] reviewed the available pieces of evidence supporting the
direct  implication  of  the  vitamin D status  in  the  development  of  osteoporosis  in  patients  affected  by  inflammatory
arthritis.
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Furthermore,  cardiovascular  diseases  are  classical  and  severe  complications  of  chronic  inflammatory  disorders,
widely  accounting  for  the  increased  mortality  observed  in  these  conditions.  The  atherogenic  profile  related  to  the
chronic inflammatory state largely contributes to the increased cardiovascular risk; nevertheless, as broadly discussed
by Bellan and Marzullo [30] in their manuscript here enclosed, vitamin D seems to play a critical role in the regulation
of the glucose metabolism, which is a primary determinant of the cardiovascular risk. If this link is generally valid in
patients affected by Type 2 Diabetes, vitamin D appears to be even more relevant in Type 1 Diabetes, in which the
aberrant activity of the immune system is essential. The impact of vitamin D status on Type I Diabetes development and
management has been discussed here by Savastio et al. [31]. Finally, original data about the influence of the antiviral
treatment on the vitamin D/parathyroid hormone axis in chronic hepatitis C have been here presented in the manuscript
by Salmi et al. [32].
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